Literature DB >> 7919360

p53 in hematologic malignancies.

J Imamura1, I Miyoshi, H P Koeffler.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7919360

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  32 in total

Review 1.  Antisense cancer therapy: the state of the science.

Authors:  D M Kushner; R H Silverman
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells.

Authors:  K C Thome; A Radfar; N Rosenberg
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  p53 gene mutations in multiple myeloma.

Authors:  R G Owen; S A Davis; J Randerson; A C Rawstron; F Davies; J A Child; A S Jack; G J Morgan
Journal:  Mol Pathol       Date:  1997-02

4.  p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization.

Authors:  M Akashi; Y Osawa; H P Koeffler; M Hachiya
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

5.  Apoptosis in haematological malignancies.

Authors:  J A DiGiuseppe; M B Kastan
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

6.  Secondary Acute Lymphoblastic Leukemia after Hodgkin's Lymphoma or a Coincidental Association of Two Hematological Malignancies?

Authors:  Mihaela Tevet; Cornel Dragan; Carmen Saguna; Doina Barbu; Anca Roxana Lupu
Journal:  Maedica (Buchar)       Date:  2013-09

7.  Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.

Authors:  Emmanuelle Boulanger; Agnès Marchio; Saw-See Hong; Pascal Pineau
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 8.  Molecular biology of leukemia for the clinician.

Authors:  E Paietta
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

9.  Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.

Authors:  Dong-Hoon Kim
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

10.  An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.

Authors:  Ramzi M Mohammad; Jack Wu; Asfar S Azmi; Amro Aboukameel; Angela Sosin; Sherwin Wu; Dajun Yang; Shaomeng Wang; Ayad M Al-Katib
Journal:  Mol Cancer       Date:  2009-12-03       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.